An interventional study of Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium in Glioblastoma, Brain Tumors and Brain Imaging, sponsored by Beta Emitting Accurate Monitored Systems. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Beta Emitting Accurate Monitored Systems · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Glioblastoma with a site in France — 35 open to participants now, 51 under way, 9 of them phase 3. Glioblastoma · France.
Among the 150 studies in Glioblastoma with a site in France, this one is the 123rd largest by planned enrollment of the 131 interventional ones that give a count, is one of 8 that started in 2026, is one of 28 with no phase, reaches primary completion later than 21 of the 50 other live ones, and was the 144th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →35 of the 150 studies in Glioblastoma with a site in France are open now. Recruiting first, the newest first:
Centre Paul Strauss · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
Centre Paul Strauss · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in France, United States, Belgium and 3 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 58 · Phase 3 27 · Phase 4 1
First in 1999; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 80 across the 131 interventional studies, 114 across the 18 observational. Of the 92 that completed or were terminated, 23 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 150 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Beta Emitting Accurate Monitored Systems as lead sponsor.
Beta Emitting Accurate Monitored Systems has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
14 of the studies in Glioblastoma with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03663725Phase 3Centre Oscar LambretTreatment Intensification With Temozolomide in Adults With a Glioblastoma | 2027-06 |
| NCT05904119Phase 3European Organisation for Research and Treatment of Cancer - EORTCLomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | 2027-09 |
| NCT04881032Centre Jean PerrinAGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT06001281Assistance Publique Hopitaux De MarseillePredictive Value of Soluble CD146 in Glioblastoma Patients | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 150 studies in Glioblastoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma. The study also seeks to validate specific nuclear imaging parameters for better detection of residual tumor tissue compared to standard gadolinium-enhanced MRI. The main objectives are to determine whether early PET-MRI within 48 hours post-surgery is feasible, to assess potential side effects related to imaging procedures, and to explore if PET parameters such as SUVmax, metabolic volume, and tumor-to-striatum ratio can improve the detection of tumor residue. A total of 15 patients will be included at a single site in France. Participants will undergo PET-MRI using 18F-DOPA and gadolinium, and will be monitored for radiation exposure and possible adverse events up to 24 hours after imaging.
This study aims to assess safety and feasibility of early post-operative PET-MRI and validate imaging parameters for detecting glioblastoma residue, enabling future personalized post-surgical care.
The primary objectives are to :
It is a prospective interventional diagnostic study involving patient comparison Category RIPH. 15 patients will be included. This is a monocentric study. One surgical and including site (CHU Henri Mondor), in one country (France).
Patients will participate during 24 hours. The duration of the study is 12 months.
Following gadolinium injection, patients will be monitored for at least 30 minutes to allow for the early detection of potential side effects. Immediate hypersensitivity reactions, including anaphylactoid responses or other idiosyncratic effects, may present with cardiovascular, respiratory, or cutaneous symptoms, and can be severe.
Although delayed reactions are rare, most immediate events occur within the first 30 minutes post-administration. Monitoring is routinely implemented in clinical practice and will be applied accordingly in the study.
18F-DOPA injection can induce pain at the injection site, probably due to the acidity of the product. Given the minimal quantity of substance administered, the primary risk is associated with the exposure to ionizing radiation. In theory, such exposure may induce carcinogenesis or result in the development of hereditary defects. Nevertheless, since the effective dose is approximately 7 mSv and we are well below the maximum recommended activity of 280 MBq, the probability of these adverse effects occurring is considered very low.
2. MRI
For PET-MRI imaging, tracer administration and acquisition timing will follow standard clinical protocols. For 18F-DOPA, a static brain acquisition will be performed between 10- and 30-minutes post-injection, as recommended for glioma imaging.
Study design is as follow :
Patients usually undergo preoperative brain PET-MRI with gadolinium enhancement and 18F-DOPA injection as a standard of care. No specific period of time will be necessary to schedule the surgery after this imaging.
Between D0 post-surgery and D2: patient informed consent and inclusion
For suspected glioblastoma:
18F-Dopa 2MBq/kg, starting the imaging immediately after injection
No medicinal product with therapeutic intent are administered in this study, only imaging agents usually used in clinical practice for diagnostic purposes are employed. The remainder of the patient's care will be managed according to the standard of care.
Only diagnostic imaging agents routinely used in standard clinical neuroimaging protocols will be administered during the study.
Gadolinium-based contrast agents will be used for MRI sequences requiring enhancement.
For PET imaging, 18F-DOPA will be employed. All imaging agents will be used under standard clinical conditions, in accordance with current safety and administration guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
non-inclusion Criteria:
Exclusion criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will undergo early post-operative PET-MRI imaging within 48 hours after surgical resection of a suspected glioblastoma. The imaging procedure includes a brain MRI with gadolinium-based contrast and a PET scan using 18F-DOPA as the radiotracer. Patients will be monitored for potential adverse events related to the imaging agents and for radiation exposure. No therapeutic intervention will be administered. The purpose of this diagnostic intervention is to assess feasibility, safety, and imaging performance in detecting residual tumor tissue.
Diagnostic Test: Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium
This intervention consists of a combined brain PET-MRI imaging session performed within 48 hours after surgical resection of a suspected glioblastoma. The PET scan uses 18F-DOPA as the radiotracer, administered intravenously at a dose of 2 MBq/kg, with static brain acquisition starting immediately post-injection. The MRI includes standard sequences and gadolinium-based contrast-enhanced imaging. The goal is to assess the feasibility and safety of this early post-operative imaging procedure, and to validate imaging parameters for the detection of residual tumor. Radiation dosimetry and potential adverse events related to imaging agents will be monitored.
Assess the feasibility of performing early post-operative brain PET-MRI in neurosurgery patients
by recording the rate of patients excluded after inclusion for non-realized imaging or incomplete imaging, at the physician's or the patient's demand.
Time frame: Within 24 hours after surgery
Assess the safety of performing early post-operative brain PET-MRI in neurosurgery patients
by collecting side effects associated with radiotracer injection and imaging procedure after surgery during the inclusion period
Time frame: Within 24 hours after surgery
Assess the safety of performing early post-operative brain PET-MRI in neurosurgery patients
by measuring ambient gamma dose rate at several time points (Hour 0, Hour 1, Hour 2, Hour 4 et Hour 24) on different points according to appendix.
Time frame: Whithin 24 hours after surgery
Assess the safety of performing early post-operative brain PET-MRI in neurosurgery patients
by measuring ambient gamma dose rate at several time points on different points (on the patient, 50 centimeters, 1 meter, 2 meters from the patient) according to appendix.
Time frame: Whithin 24 hours afin surgery
Assess the safety of performing early post-operative brain PET-MRI in neurosurgery patients
With total dosimetry after 24 hours
Time frame: Whithin 24 hours afin surgery
Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients
by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Dynamic analysis including peak time
Time frame: 24 hours
Evaluate the inter-raters reliability of nuclear imaging protocol (T/S and T/CC) to evaluate the presence or absence of residual tumor on early post-operative brain PET in neurosurgery patients.
Images will be reviewed by at least two raters : Kappa coefficient, Percentage agreement
Time frame: 24 hours
Evaluate the inter-raters reliability of nuclear imaging protocol (metabolic volume with different thresholds) to measure residual tumor volume on early post-operative brain PET in neurosurgery patients.
Intra-class correlation coefficient
Time frame: 24 hours
Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients
by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Dynamic analysis including sleigh
Time frame: 24 hours
Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients
by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Dynamic analysis including wash-out period
Time frame: 24 hours
Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients
by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Standardized Uptake Value maximum
Time frame: 24 hours
Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients
by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: Tumour/Striatum ratio (T/S)
Time frame: 24 hours
Validate a nuclear imaging protocol to measure residual tumor volume on early post-operative brain PET-MRI in neurosurgery patients
by varying different parameters in PET analysis and comparing the results with gadolinium enhanced MRI: The rate of discordance between MRI result and PET result will be assessed for each modality
Time frame: 24 hours
Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
Of 151 interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 88. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.